Dublin, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The "RNAi Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030" report has been added to ResearchAndMarkets.com's offering.
The global RNAi therapeutics market was valued at USD 11.20 billion in 2022 and is expected to reach USD 20.23 billion in 2030, with a CAGR of a 7.69% during the forecast period 2023-2030. The study on RNAi therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030. 
The report on RNAi therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global RNAi therapeutics market over the period of 2021-2030. The Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global RNAi therapeutics market over the period of 2021-2030. The report's Growth Matrix provides insight into the investment areas that existing or new market players can consider.
Key Market Dynamics
Drivers
- The substantial growth in the RNAi therapeutics market is strongly influenced by heightened research and development efforts aimed at addressing chronic diseases.
- The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market.
Restraints
- Complex delivery mechanisms hinder RNAi therapeutics market.
Opportunities
- Technological breakthroughs in delivery technology have increased the number of indications for RNAi therapeutics, provides an opportunity for the market to grow.
Report Segmentation
The global RNAi therapeutics market is segmented on the basis of type, application, route of administration, and end user.
The Global RNAi Therapeutics Market by Type
- Small interfering RNA (siRNA)
- MicroRNA (miRNA)
The Global RNAi Therapeutics Market by Application
- Genetic Disorders
- Oncology
- Neurodegenerative Disorders
- Infectious Diseases
- Renal Diseases
- Others
The Global RNAi Therapeutics Market by Route of Administration
- Intradermal Injections
- Pulmonary Delivery
- Intravenous Injections
The Global RNAi Therapeutics Market by End User
- Diagnostic Laboratories
- Research and Academic Laboratories
- Hospitals
Company Profiles
- Alnylam Pharmaceuticals
- QIAGEN
- Olix Pharmaceuticals
- Arbutus Biopharma
- Silence Therapeutics
- Dicerna Pharmaceuticals
- Arrowhead Pharmaceuticals
- Quark Software
- Phio Pharmaceuticals
- Benitec Biopharma
What does this Report Deliver?
- Comprehensive analysis of the global as well as regional markets of the RNAi therapeutics market.
- Complete coverage of all the segments in the RNAi therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2030.
- Comprehensive analysis of the companies operating in the global RNAi therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 180 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $11.2 Billion |
| Forecasted Market Value (USD) by 2030 | $20.23 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/gb84qx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
